Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc. Common Stock (AARD) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
aard · stock forecast · 9 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$47.00
Consensus
$22.75
+533.7% upside
Low
$3.00
Median: $20.5 · Last Close: $3.59
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$22.75
533.7% upside
High Target
$47
1209.2%
Low Target
$3
-16.4%
Current Price
$3.59
as of today
Based on analyst price targets, the AARD stock price prediction for the next 12 months ranges from $3 to $47. The consensus AARD price forecast of $22.75 implies 533.7% upside from the current price of $3.59.
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $3.41 | ↓ 5.00% |
1-day model range: $3.35–$3.47. Peak: $3.47 (-5.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · AARD · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-15 | Morgan Stanley | Downgrade ↓ | Equal Weight→Underweight |
| 2026-05-15 | BTIG | Downgrade ↓ | Buy→Neutral |
| 2026-05-15 | B. Riley Securities | Maintains | Buy→Buy |
| 2026-03-24 | BTIG | Maintains | Buy→Buy |
| 2026-03-02 | BTIG | Maintains | Buy→Buy |
| 2026-03-02 | Morgan Stanley | Downgrade ↓ | Overweight→Equal Weight |
| 2026-03-02 | RBC Capital | Downgrade ↓ | Outperform→Sector Perform |
| 2026-03-02 | Stifel | Downgrade ↓ | Buy→Hold |
| 2026-03-02 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2026-03-02 | Oppenheimer | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Aardvark Therapeutics, Inc. Common Stock (AARD) stock. Of the recent 20 rating actions, 0 were upgrades and 6 were downgrades. 9 analysts currently cover AARD.
Analyst Recommendation Trends
AARD analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 95.5% YoY
Revenue Next Year
$1M
↑ 242.0% YoY
EPS This Year
$-3.59
EPS Next Year
$-3.26
↓ 9.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast AARD EPS of $-3.59 for the current fiscal year, based on estimates from 9 analysts. The AARD revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AARD stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AARD price target is $22.75 (+533.7% upside), with an analyst consensus of Buy.
The AARD short-term stock prediction for tomorrow is $3.41 (-5.00%).
Aardvark Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker AARD. The AARD stock outlook for 2027 is broadly positive, supported by a Buy consensus among 44% of covering analysts.
Frequently asked questions
AARD forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month AARD price target is $22.75, with a high forecast of $47.00 and a low of $3.00. The median price target is shown in the chart above when available. This implies +533.7% potential upside from the current price of $3.59.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.